MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, announced today the availability of a new white paper focused on gummy products, its revolutionary gummy technology, titled “Revolutionary Gummy Technology That Solves for The Supply Chain Constraints of Other Gummy Formats and Enhances Consumer Experience”.
The white paper explores how brands, manufacturers, and suppliers of VMS (Vitamins, Minerals and Supplements) products today face the challenge of ensuring that their products can maintain their quality and integrity across the different steps involved during the supply chain distribution, particularly during summer season. During the stages of storage, loading, unloading and transportation, the high sensitivity of gummies to temperature fluctuation poses the most significant challenge.
The white paper introduces Funtrition®, a division of Procaps and leading developer and manufacturer of innovative gummy technologies, that has been working for years on extensive research and development in new technology platforms that can solve any type of formulation challenges, bringing exciting products to consumers, while elevating sensorial experiences, and now, overcoming critical challenges that could potentially affect the product during its distribution.
“Gummy safety and quality are an urgent concern for many organizations that are faced with increasing strict marketplace requirements,” said Camilo Camacho, COO of Procaps Group. “Amazon for example has implemented a ‘Meltable Product Shipping Policy’ requiring brands to ensure their products meet quality standards and are not susceptible to melting during the stages of storage and transportation.”
“This white paper demonstrates how Funtrition meets these challenges with its revolutionary technology that increases the thermal resistance of the gummies. We hope this white paper will be an accessible, practical highlight for investors showing Procaps’ development of innovative technologies to meet evolving market demands and requirements,” said Ruben Minski, CEO of Procaps Group.
The white paper, provided by Procaps, can be downloaded by visiting: https://www.naturalproductsinsider.com/contract-manufacturing/revolutionary-gummy-technology-solves-supply-chain-challenges-and-enhances
About Procaps Group
Procaps (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,300 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional supplements, and high-potency clinical solutions.
For more information, visit www.procapsgroup.com or Procaps’ investor relations website investor.procapsgroup.com.
Forward Looking Statements
This press release includes “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include projected financial information. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks included under the header “Risk Factors” in Procaps’ annual report on Form 20-F filed with the SEC, as well as Procaps’ other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
